Wegovy and Ozempic are the same molecule, semaglutide, sold under two licences that stop at different doses. Ozempic is licensed for type 2 diabetes with a 2 mg ceiling. Wegovy is licensed for chronic weight management and maintains at 2.4 mg, with a 7.2 mg version approved in the United States in March 2026.
That difference is not cosmetic, and it is not mainly about the extra 0.4 mg. The two brands were taken through separate trial programmes that enrolled different people and measured different endpoints, so almost every number attached to one of them cannot be moved to the other.
The two licences side by side
Nothing in this table is about which drug is stronger. It is about what each product is approved to do and what evidence sits behind that approval.
| Ozempic | Wegovy | |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Primary indication | Type 2 diabetes, as an adjunct to diet and exercise | Chronic weight management in obesity, or overweight with a weight-related condition |
| Maximum labelled dose | 2 mg once weekly | 2.4 mg maintenance; 7.2 mg version since March 2026 |
| Added indications | Reducing major adverse cardiovascular events in type 2 diabetes with heart disease; since January 2025, reducing worsening kidney disease and cardiovascular death in type 2 diabetes with chronic kidney disease | Since March 2024, reducing major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity |
| Cardiovascular trial | SUSTAIN-6, 0.5 mg and 1 mg, 3297 adults with type 2 diabetes (PMID 27633186) | SELECT, 2.4 mg, 17,604 adults with cardiovascular disease and no diabetes (PMID 37952131) |
| Flagship efficacy trial | SUSTAIN FORTE, 1 mg vs 2 mg, HbA1c endpoint (PMID 34293304) | STEP 1, 2.4 mg vs placebo, body weight endpoint (PMID 33567185) |
There is no head-to-head trial
This is the part worth being pedantic about, because the internet is full of a comparison that does not exist. Nobody has run Ozempic against Wegovy in the same trial. The figures people place side by side come from separate programmes:
- STEP 1: semaglutide 2.4 mg, adults with overweight or obesity and no diabetes, 68 weeks, mean weight change -14.9% against -2.4% on placebo (PMID 33567185).
- SUSTAIN FORTE: semaglutide 2 mg against 1 mg, adults with type 2 diabetes on metformin, 40 weeks, mean weight change -6.9 kg against -6.0 kg (PMID 34293304).
Put those next to each other and you have a percentage against a kilogram figure, 68 weeks against 40, and people without diabetes against people with it. Three of those four differences would each move the answer on their own. STEP 2 makes the population effect concrete: the identical 2.4 mg dose over the identical 68 weeks produced -9.6% in adults who also had type 2 diabetes, about a third less than STEP 1 (PMID 33667417).
So the honest version of the comparison is narrower than the popular one. Wegovy reaches a higher dose, and the higher-dose trials were run in a population that loses more weight on semaglutide in the first place. How much of the gap belongs to the dose and how much to the population is not something the published trials can separate.
What SELECT does and does not show
SELECT enrolled 17,604 adults aged 45 or over with established cardiovascular disease, a BMI of 27 or more and no diabetes, and randomised them to semaglutide 2.4 mg or placebo. A first cardiovascular death, non-fatal heart attack or non-fatal stroke occurred in 6.5% of the semaglutide group and 8.0% of the placebo group over a mean 39.8 months of follow-up, a hazard ratio of 0.80 (PMID 37952131). That result is what added a cardiovascular indication to the Wegovy label in March 2024.
SELECT is a cardiovascular outcomes trial. It does not report a headline weight loss percentage, and quoting it as a weight loss result is a common error worth not repeating. For Ozempic, the equivalent evidence is SUSTAIN-6, which used 0.5 mg and 1 mg in 3297 adults with type 2 diabetes over 104 weeks and found the same composite endpoint in 6.6% against 8.9% on placebo, a hazard ratio of 0.74 (PMID 27633186).
Two trials, two populations, two dose ranges, both showing fewer cardiovascular events. Neither tells you anything about the other brand.
Where the practical difference actually lands
For most people choosing between these two, the deciding factors are not pharmacological.
- Diagnosis. Ozempic is prescribed for type 2 diabetes. Wegovy is prescribed for weight management. Which label fits is a clinical question, and insurers read the indication closely.
- Coverage and cash price. Both manufacturers now publish self-pay prices. As of late September 2026 NovoCare Pharmacy lists Wegovy at $349 a month across the 0.25 mg to 2.4 mg doses and $399 for the 7.2 mg version, and Ozempic at $349 a month for 0.25 mg, 0.5 mg and 1 mg with $499 for the 2 mg dose. Prices in these programmes move, so check the current figure before budgeting.
- The dose you end up on. Ozempic’s 0.5 mg and 1 mg are licensed maintenance doses, so plenty of people stay there indefinitely. On the Wegovy ladder the intermediate doses are steps toward 2.4 mg.
- Formulation. Since January 2026 the weight management licence also covers an oral 25 mg tablet, which has no Ozempic-injection equivalent at that indication. We compared the two formats in Wegovy pill vs injection.
What this comparison is not
It is not a dosing guide. The two escalation ladders, including the weeks at each step, are laid out in our semaglutide dosage chart and in more detail for one brand in the Ozempic dosage chart. Neither article, and not this one, is a reason to change what you are taking.
It is also not a prediction. A trial average is a population figure, and the spread inside STEP 1 was wide: 50.5% of participants lost at least 15% of their starting weight while others lost almost nothing.
Turn the trial percentages into your own numbers
See what STEP 1 and STEP 2 work out to in pounds from your starting weight.
FAQ
Is Wegovy just a higher dose of Ozempic?
Same molecule, different licence. Ozempic is approved for type 2 diabetes to a 2 mg maximum, Wegovy for chronic weight management with a 2.4 mg maintenance dose and a 7.2 mg version approved in March 2026. They are separate products with separate prescribing information, not two box sizes of one thing.
Which loses more weight, Wegovy or Ozempic?
No trial has compared them. The trial evidence behind Wegovy uses 2.4 mg and reports percentage weight change, and the trial evidence behind Ozempic uses 1 mg and 2 mg and reports HbA1c with weight as a secondary outcome. The higher dose and the different populations both push the published Wegovy figures higher, and the two effects cannot be separated from the data.
Can Ozempic be prescribed for weight loss?
It is not licensed for it in the United States, where weight management is Wegovy’s indication. Whether an off-label prescription is appropriate is a matter for a prescriber, and insurers generally follow the licensed indication when deciding coverage.
Does Ozempic have the same heart benefit as Wegovy?
Each has its own evidence in its own population. SUSTAIN-6 studied 0.5 mg and 1 mg in adults with type 2 diabetes and found the composite cardiovascular endpoint in 6.6% against 8.9% on placebo. SELECT studied 2.4 mg in adults with cardiovascular disease and no diabetes and found 6.5% against 8.0%. Both labels carry a cardiovascular indication, worded for the population that was studied.
Why is Wegovy often more expensive than Ozempic?
Mostly coverage rather than list price. Weight management drugs are excluded from many United States insurance plans while diabetes drugs are routinely covered, so more Wegovy prescriptions land on self-pay pricing. As of late September 2026 the manufacturer self-pay prices are close: $349 a month for standard Wegovy doses against $349 to $499 for Ozempic depending on dose.
Sources
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
- Davies M, Faerch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. PMID: 33667417
- Frias JP, Auerbach P, Bajaj HS, et al. Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE). Lancet Diabetes Endocrinol. 2021;9(9):563-574. PMID: 34293304
- Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834-1844. PMID: 27633186
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131
- Ozempic and Wegovy prescribing information, Novo Nordisk. Indications, dosage and administration.
- NovoCare Pharmacy published self-pay prices, checked 29 September 2026.
This article is for information only and is not medical advice. Dosing, suitability and any change to treatment are decisions for your prescriber.